2019 Review Course Learning Objectives and CME
The ASPHO Review Course is designed for physicians preparing for the American Board of Pediatrics (ABP) examination for initial certification in pediatric hematology/oncology as well as fellows in training and practitioners seeking a thorough review and update of the established standards of care for pediatric patients with cancer and blood disorders.
As a result of attending this course, participants should be able to
- describe the basic pathophysiology of hematologic disease and cancer in infants, children, and adolescents, including molecular and cellular biology, the genetic and biochemical basis of disease, and the fundamentals of morphology and disease classification
- discuss the differential diagnosis, management, and outcomes of the hematologic disorders and malignancies encountered in practice by pediatric hematology/oncology specialists
- explain fundamental concepts of biostatistics, epidemiology and outcomes analysis, and engagement in scholarly activities as these areas apply to the field of pediatric hematology/oncology
- analyze the principles and practice of stem cell transplantation, transfusion medicine, and supportive care in children with hematologic disease and cancer, along with the basic principles of immunology and the most common immunologic disorders encountered by the hematologist
- prepare for the hematology/oncology subboard examination offered by the ABP and subsequent questions and examinations aimed at future Maintenance of Certification 3 requirements.
Continuing Medical Education (CME)
The American Society of Pediatric Hematology/Oncology (ASPHO) will offer CME credit for those sessions attended and evaluated. A certificate will be issued upon completion of the evaluation.
The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 27 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ASPHO offers its course evaluation in an online format that can be accessed by visiting www.aspho.org/course. The online evaluation may be completed during the course or after attendees have returned home. Participants receive their certificates immediately when they submit their evaluation. We encourage all attendees to complete their evaluation regardless of whether they are seeking CME credit.
ASPHO requires that planners and presenters disclose the existence of any relevant financial or other relationship they and/or their spouse/partner have with the manufacturers of any commercial interest (defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients) whose products or services relate to the topics presented. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product. The ASPHO Accreditation Subcommittee of the Education Committee reviews potential conflicts of interest as submitted by planners and presenters and resolves such conflicts to ensure the content of the activity is aligned with the interests of the public.
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.
Review Course Committee
The committee is responsible for the course content, and faculty recruitment and development, with attention to the American Board of Pediatrics subspecialty topic content, feedback from participants and changing requirements of maintenance of certification. The committee also directs the online review course program. View the 2019 Review Course Committee.
No relevant financial relationships and no discussion of off-label drug use:
Jennifer C. Kesselheim; Michael Anderson; Matthew Oberley; Patrick A. Brown; Paul Harker-Murray; Mark D. Fleming; Melissa Frei-Jones; Matthew Heeney; Carlos Rodriguez-Galindo; Guy Young; Carl Allen; Rowena Punzalan; Karen Effininger
No relevant financial relationships; off-label drug use discussed:
Leo Mascarenhas; Sun-Yun Pai; Kenneth L. McClain; David O. Walterhouse; Mignon Loh; Denise M. Adams; Julie R. Park; Jenny Moran
Relevant financial relationships and no discussion of off-label drug use:
Rachael Grace: Agios Pharmaceuticals- Clinical research, research funding; Zora R. Rogers: BCT Terumo-Medical monitor for clinical trial, honorarium; Jason Fangusaro: Celgene-Pediatric oversight group, honorarium; Michael Pulsipher: Novartis-Advisory board, honorarium
Relevant financial relationships; off-label drug use discussed:
Cindy E. Neunert: Sanofi-Genzyme-Consultant, consultant fee; Sarah H. O’Brien: Bristol Myers Squibb-PI, research support
Educational Support Acknowledgement:
ASPHO extends it appreciation to the following organizations for their education support of the Review Course:
Novartis Pharmaceuticals Corporation